In the past week, BLUE stock has gone down by -7.53%, with a monthly gain of 4.02% and a quarterly plunge of -24.35%. The volatility ratio for the week is 10.75%, and the volatility levels for the last 30 days are 21.85% for Bluebird bio Inc The simple moving average for the past 20 days is -8.13% for BLUE’s stock, with a -50.11% simple moving average for the past 200 days.
Is It Worth Investing in Bluebird bio Inc (NASDAQ: BLUE) Right Now?
BLUE has 36-month beta value of 0.70. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 6 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BLUE is 9.64M, and currently, short sellers hold a 25.71% ratio of that float. The average trading volume of BLUE on December 31, 2024 was 419.87K shares.
BLUE) stock’s latest price update
Bluebird bio Inc (NASDAQ: BLUE) has experienced a decline in its stock price by -10.48 compared to its previous closing price of 8.78. However, the company has seen a fall of -7.53% in its stock price over the last five trading days. businesswire.com reported 2024-12-08 that SOMERVILLE, Mass.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE) today announced new and updated data from LYFGENIA™ (lovotobegligene autotemcel, or lovo-cel) gene therapy for patients with sickle cell disease who have a history of vaso-occlusive events (VOEs). The data will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in an oral presentation on Sunday, December 8 at 9:30 a.m. Pacific Time and a poster presentation on Sunday, December 8 at 6 p.
Analysts’ Opinion of BLUE
BofA Securities, on the other hand, stated in their research note that they expect to see BLUE reach a price target of $0.50, previously predicting the price at $3. The rating they have provided for BLUE stocks is “Neutral” according to the report published on November 15th, 2024.
BLUE Trading at -6.64% from the 50-Day Moving Average
After a stumble in the market that brought BLUE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.53% of loss for the given period.
Volatility was left at 21.85%, however, over the last 30 days, the volatility rate increased by 10.75%, as shares sank -2.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.22% lower at present.
During the last 5 trading sessions, BLUE fell by -7.53%, which changed the moving average for the period of 200-days by -70.45% in comparison to the 20-day moving average, which settled at $8.56. In addition, Bluebird bio Inc saw -71.52% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BLUE starting from Obenshain Andrew, who sale 971 shares at the price of $0.42 back on Dec 10 ’24. After this action, Obenshain Andrew now owns 374,247 shares of Bluebird bio Inc, valued at $405 using the latest closing price.
Colvin Richard A, the Chief Medical Officer of Bluebird bio Inc, sale 2,824 shares at $0.42 during a trade that took place back on Dec 10 ’24, which means that Colvin Richard A is holding 165,544 shares at $1,178 based on the most recent closing price.
Stock Fundamentals for BLUE
Current profitability levels for the company are sitting at:
- -5.96 for the present operating margin
- -0.43 for the gross margin
The net margin for Bluebird bio Inc stands at -5.66. The total capital return value is set at -1.87. Equity return is now at value -270.20, with -54.29 for asset returns.
Based on Bluebird bio Inc (BLUE), the company’s capital structure generated 1.09 points at debt to capital in total, while cash flow to debt ratio is standing at -3.17. The debt to equity ratio resting at -12.2. The interest coverage ratio of the stock is -19.69.
Currently, EBITDA for the company is -167.16 million with net debt to EBITDA at -2.32. When we switch over and look at the enterprise to sales, we see a ratio of 7.04. The receivables turnover for the company is 3.71for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.51.
Conclusion
To put it simply, Bluebird bio Inc (BLUE) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
